The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.
The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.
*Sign up for news summaries and alerts from 340B Report